Top

Published in:

Open Access 01-12-2019 | Fatty Liver | Research article

Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial

Authors: Saeede Saadati, Amir Sadeghi, Asieh Mansour, Zahra Yari, Hossein Poustchi, Mehdi Hedayati, Behzad Hatami, Azita Hekmatdoost

Published in: BMC Gastroenterology | Issue 1/2019

Abstract

Background

The aim of the present study was to evaluate the effects of curcumin supplementation on inflammatory indices, and hepatic features in patients with non-alcoholic fatty liver disease (NAFLD).

Methods

Fifty patients with NAFLD were randomized to receive lifestyle modification advice plus either 1500 mg curcumin or the same amount of placebo for 12 weeks.

Results

Curcumin supplementation was associated with significant decrease in hepatic fibrosis (p < 0.001), and nuclear factor-kappa B activity (p < 0.05) as compared with the baseline. Hepatic steatosis and serum level of liver enzymes, and tumor necrosis-α (TNF-α) significantly reduced in both groups (p < 0.05). None of the changes were significantly different between two groups.

Conclusion

Our results indicated that curcumin supplementation plus lifestyle modification is not superior to lifestyle modification alone in amelioration of inflammation.

Trial registration

IRCT20100524004010N24, this trial was retrospectively registered on May 14, 2018.

Mokhtari Z, Gibson DL, Hekmatdoost A. Nonalcoholic fatty liver disease, the gut microbiome, and diet. Adv Nutr. 2017;8(2):240–52.PubMedPubMedCentralCrossRef

Younossi ZM. Non-alcoholic fatty liver disease—a global public health perspective. J Hepatol. 2019;70(3):531–44.PubMedCrossRef

Eslamparast T, et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99(3):535–42.PubMedCrossRef

Foschi FG, et al. Prevalence of and risk factors for fatty liver in the general population of northern Italy: the Bagnacavallo study. BMC Gastroenterol. 2018;18(1):177.PubMedPubMedCentralCrossRef

Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1):S47–64.PubMedCrossRef

Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–48.PubMedCrossRef

Darand M, Alavian SM, Hekmatdoost A. Nigella sativa and non-alcoholic fatty liver disease: a review of the current evidence. Hepat Mon. 2018;18:9.

Ghaemi A, et al. How much weight loss is effective on nonalcoholic fatty liver disease? Hepat Mon. 2013;13(12).

Emamat H, et al. The effects of onion consumption on treatment of metabolic, histologic, and inflammatory features of nonalcoholic fatty liver disease. J Diabetes Metab Disord. 2015;15:25.PubMedCrossRef

10.

Hekmatdoost A, et al. Adherence to the dietary approaches to stop hypertension (DASH) and risk of nonalcoholic fatty liver disease. Int J Food Sci Nutr. 2016;67(8):1024–9.PubMedCrossRef

11.

Mokhtari Z, et al. Egg consumption and risk of non-alcoholic fatty liver disease. World J Hepatol. 2017;9(10):503–9.PubMedPubMedCentralCrossRef

12.

Noori M, Jafari B, Hekmatdoost A. Pomegranate juice prevents development of non-alcoholic fatty liver disease in rats by attenuating oxidative stress and inflammation. J Sci Food Agric. 2017;97(8):2327–32.PubMedCrossRef

13.

Rahimlou M, Ahmadnia H, Hekmatdoost A. Dietary supplements and pediatric non-alcoholic fatty liver disease: present and the future. World J Hepatol. 2015;7(25):2597–602.PubMedPubMedCentralCrossRef

14.

Rahimlou M, et al. Ginger supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Hepat Mon. 2016;16(1):e34897.PubMedPubMedCentralCrossRef

15.

Panahi Y, et al. Mitigation of systemic oxidative stress by Curcuminoids in osteoarthritis: results of a randomized controlled trial. J Diet Suppl. 2016;13(2):209–20.PubMedCrossRef

16.

Alm-Eldeen AA, et al. Synergistic effect of black tea and curcumin in improving the hepatotoxicity induced by aflatoxin B1 in rats. Toxicol Ind Health. 2015;31(12):1269–80.PubMedCrossRef

17.

Dattani J, et al. Ameliorative effect of curcumin on hepatotoxicity induced by chloroquine phosphate. Environ Toxicol Pharmacol. 2010;30(2):103–9.PubMedCrossRef

18.

Coban D, et al. Dietary curcumin inhibits atherosclerosis by affecting the expression of genes involved in leukocyte adhesion and transendothelial migration. Mol Nutr Food Res. 2012;56(8):1270–81.PubMedCrossRef

19.

Leclercq IA, et al. Curcumin inhibits NF-κB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol. 2004;41(6):926–34.PubMedCrossRef

20.

Rahmani S, et al. Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother Res. 2016;30(9):1540–8.PubMedCrossRef

21.

Kocher A, et al. Highly bioavailable micellar curcuminoids accumulate in blood, are safe and do not reduce blood lipids and inflammation markers in moderately hyperlipidemic individuals. Mol Nutr Food Res. 2016;60(7):1555–63.PubMedCrossRef

22.

Parizadeh S.M., M. Ghayour-Mobarhan, ScientificWorldJournal.

23.

NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults (US). Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda: National Heart, Lung, and Blood Institute; 1998 Sep. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2003/.

24.

Malekzadeh R, Poustchi H. Fibroscan for assessing liver fibrosis: an acceptable alternative for liver biopsy: Fibroscan: an acceptable alternative for liver biopsy. Hepat Mon. 2011;11(3):157.PubMedPubMedCentral

25.

Ainsworth BE, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000;32(9; SUPP/1):S498–504.PubMedCrossRef

26.

Ghaffarpour M, Houshiar-Rad A, Kianfar H. The manual for household measures, cooking yields factors and edible portion of foods, vol. 7. Tehran: Nashre Olume Keshavarzy; 1999. p. 213.

27.

Kelany ME, Hakami TM, Omar AH. Curcumin improves the metabolic syndrome in high-fructose-diet-fed rats: role of TNF-α, NF-κB, and oxidative stress. Can J Physiol Pharmacol. 2016;95(2):140–50.PubMedCrossRef

28.

Maithilikarpagaselvi N, et al. Curcumin prevents inflammatory response, oxidative stress and insulin resistance in high fructose fed male Wistar rats: potential role of serine kinases. Chem Biol Interact. 2016;244:187–94.PubMedCrossRef

29.

Ramirez-Tortosa MC, et al. Curcumin ameliorates rabbits's steatohepatitis via respiratory chain, oxidative stress, and TNF-α. Free Radic Biol Med. 2009;47(7):924–31.PubMedCrossRef

30.

Cho J-W, Lee K-S, Kim C-W. Curcumin attenuates the expression of IL-1β, IL-6, and TNF-α as well as cyclin E in TNF-α-treated HaCaT cells; NF-κB and MAPKs as potential upstream targets. Int J Mol Med. 2007;19(3):469–74.PubMed

31.

Shehzad A, et al. New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur J Nutr. 2011;50(3):151–61.PubMedCrossRef

32.

Ziccardi P, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002;105(7):804–9.PubMedCrossRef

Title: Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial
Authors: Saeede Saadati
Amir Sadeghi
Asieh Mansour
Zahra Yari
Hossein Poustchi
Mehdi Hedayati
Behzad Hatami
Azita Hekmatdoost
Publication date: 01-12-2019
Publisher: BioMed Central
Keyword: Fatty Liver
Published in: BMC Gastroenterology / Issue 1/2019
Electronic ISSN: 1471-230X
DOI: https://doi.org/10.1186/s12876-019-1055-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial

Abstract

Background

Methods

Results

Conclusion

Trial registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2019

Splenic abscesses as a first manifestation of Crohn’s disease: a case report

Profile and outcome of patients with upper gastrointestinal bleeding presenting to urban emergency departments of tertiary hospitals in Tanzania

Moderate-intensity aerobic and resistance exercise is safe and favorably influences body composition in patients with quiescent Inflammatory Bowel Disease: a randomized controlled cross-over trial

Helicobacter pylori infection associated with an increased risk of colorectal adenomatous polyps in the Chinese population

Lupus enteritis masquerading as Crohn’s disease

Clinical outcomes of iatrogenic upper gastrointestinal endoscopic perforation: a 10-year study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page